Notícias e Atividades da Biomea Fusion

Biomea Fusion é uma empresa listada sob o símbolo BMEA (US).

Veja o organograma con seus 13 executivos principais

Biografias mais buscadas da Biomea Fusion

• Michael Hitchcock, Interim Chief Executive Officer
• Sumita Ray, Director
• Elizabeth Faust, Member of the Board

Criar um alerta
para seguir os movimentos de executivos da Biomea Fusion.

Biomea Fusion possui 2.405 concorrentes concorrentes Eurofins (Luxemburgo), Lonza (Suíça) e BioNTech (Alemanha).

Popular M&A news in Biotecnologia

• Laboratoire Servier has announced the acquisition of Edgewise Therapeutics  (publicado em 4 de junho de 2026).
• Oak Hill Bio acaba de anunciar uma arrecadação de fundos de 33 milhões de dólares. (publicado em 4 de junho de 2026).
• IMU Biosciences acaba de anunciar uma arrecadação de fundos de 53 milhões de dólares. (publicado em 3 de junho de 2026).

Outros contatos sugeridos na indústria do Biotecnologia

• Jakob Uszkoreit - Co-Founder and Chief Executive Officer da Inceptive
• Jan Van de Winkel - President and Chief Executive Officer da Genmab
• Valerie Hanote - Non-Executive Director da Eurofins

Saiba mais sobre a indústria do Biotecnologia

Últimos comunicados de imprensa de Biomea Fusion

• Biomea Fusion Reports Second Quarter 2022 Financial Results and Business Highlights | Biomea Fusion
• Biomea Fusion Selected for Two Oral Presentations at the European Association for the Study of Diabetes Annual Meeting Describing BMF-219’s Potential as a Novel, Oral, Long-Acting, Acute Treatment for Type 2 Diabetes | Biomea Fusion
• Biomea Fusion Announces First Patient Dosed in Multiple Myeloma Cohort of COVALENT-101 Trial | Biomea Fusion
• Biomea Fusion Presents Novel Preclinical Data at ADA 2022 Suggesting BMF-219’s Potential as an Oral, Long-Acting Treatment for Type 2 Diabetes | Biomea Fusion
• Biomea Fusion to Participate in Jefferies Healthcare Conference | Biomea Fusion
• Biomea Fusion to Present New Preclinical Data on BMF-219 in Two Diabetic Animal Models at ADA 2022 | Biomea Fusion
• Biomea Fusion to Present New Preclinical Data Showing BMF-219’s Strong Activity in Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL) Tumor Models at ASCO 2022 | Biomea Fusion
• Biomea Fusion to Attend H.C. Wainwright Global Investment Conference | Biomea Fusion
• Biomea Fusion Announces IND Candidate Selection: BMF-500, a Potential Best-in-Class Oral Covalent Inhibitor of FLT3 | Biomea Fusion
• Biomea Fusion Reports First Quarter 2022 Financial Results and Business Highlights | Biomea Fusion
• View more press releases Close

Redes sociais sobre Biomea Fusion

• Biomea Fusion na Wikipedia, Google News e Yahoo Finance
• Biomea Fusion na LinkedIn, X (Twitter) e YouTube